NIAID Career Transition Award (K22)

PAR-14-341
NIAID Career Transition Award (K22)
Department of Health and Human Servicesmulti-ethnic-scientists-in-lab-article
National Institutes of Health

Section I. Funding Opportunity Description

The overall goal of the NIH Research Career Development program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation’s biomedical, behavioral, and clinical research needs. In addition to this opportunity, NIH Institutes and Centers (ICs) support a variety of other mentored career development programs designed to foster the transition of new investigators to research independence. These other programs may be more suitable for particular candidates.  NIH also supports non-mentored career development programs for independent investigators. More information about Career programs may be found at the NIH Extramural Training Mechanisms website.

The objective of the of the NIAID Career Transition Award is to support postdoctoral fellows transitioning to positions of assistant professor or equivalent, and initiate a successful biomedical career as an independent research scientist.

NIH believes that the creativity and innovation of new independent investigators in their early career stages play an integral role in addressing our Nation’s biomedical, behavioral, and clinical research needs. However, the average age of first-time (new) Principal Investigators obtaining R01 research funding from the NIH has risen to 42 years for Ph.D. degree holders and 44 years for M.D./Ph.D. degree holders in 2013. The intent of the NIAID K22 program is to help alleviate this trend and to assist new investigators in transitioning to stable independent research positions at an earlier age and with an enhanced probability of success in obtaining independent NIH or other independent research support.

Nature of the career/research transition opportunity

The K22 award will provide two years of support to conduct biomedical research as an independent scientist at an extramural sponsoring institution/organization to which the individual has been recruited, been offered and has accepted a tenure-track full-time assistant professor position (or equivalent). This support is to allow the individual to continue to work toward establishing his/her own independent research program and prepare an application for regular research grant support (R01).

The postdoctoral fellow, also referred to as a candidate, submits a K22 application from the institution where s/he currently pursues his/her postdoctoral research training.  The application will be peer reviewed and assigned an overall impact score.  Successful candidates (i.e. whose application has received a fundable overall impact score) will receive an approval letter from NIAID that will include the terms and conditions to activate the K22 award. In order to activate the K22 award, the candidate will need to secure a tenure-track full-time assistant professor position within a year of the receipt of the approval letter.  Once the assistant professor position has been secured, the candidate will submit updated information about the K22 application with the support of the sponsoring institution.  The sponsoring institution can be the same as the post-doctoral institution, though it is most likely a different institution from the original submission of the K22 application.  The updated information of the transition to an assistant professor position at the sponsoring institution will be evaluated by senior NIAID staff to ensure that all programmatic requirements are met prior to the activation of the K22 award. The details of the requirements for the activation of the K22 award are described in Section VI of this announcement.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-14-341
Funding Opportunity Title: NIAID Career Transition Award (K22)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:  
Expected Number of Awards:  
CFDA Number(s): 93.855 — Allergy, Immunology and Transplantation Research
93.856 — Microbiology and Infectious Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Sep 12, 2014
Last Updated Date: Sep 16, 2016
Original Closing Date for Applications: Sep 07, 2017  
Current Closing Date for Applications: Sep 16, 2016  
Archive Date: Oct 16, 2016
Estimated Total Program Funding:  
Award Ceiling:  
Award Floor:  

Eligibility

Eligible Applicants: Small businesses
Special district governments
County governments
City or township governments
Native American tribal governments (Federally recognized)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Private institutions of higher education
State governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of the NIAID Career Transition Award (CTA) program is to increase and maintain a strong cohort of new and talented NIH-supported independent investigators that will address the health needs of the Nation. The NIAID CTA is specifically designed to facilitate the transition from a postdoctoral research position to an independent research position.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-14-341.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)

PAR-16-318
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)
Department of Health and Human Services
National Institutes of Health

breast-cancer-caregivers
Breast cancer care
Purpose

This purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions designed to support caregivers of adult cancer patients. Interventions that are appropriate for this FOA may be intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications submitted to this FOA should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications. Whereas this FOA is for pilot/exploratory projects, a companion FOA of identical scientific scope (PAR-16-317) is meant for well-developed projects supported by preliminary data.

Background

Informal/family cancer caregivers are individuals who manage care for cancer patients, usually a friend or family member. The care that they manage is typically uncompensated, delivered at home, involves significant amounts of time and energy, and requires the performance of tasks that may be physically, emotionally, socially, or financially demanding. Caregiving tasks can include monitoring for treatment side effects, helping manage symptom burden, treatment decision-making, administering medication, and performing some technical medical tasks (e.g., managing infusion ports, changing dressings). Cancer treatment is now more frequently provided in outpatient and community-based centers, which increases the day-to-day demands on informal caregivers. As lay supporters, caregivers are often underprepared to perform the many tasks required of them and this can lead to negative health consequences. Given that the prevalence of people, in particular older adults, living with cancer is growing, the number of cancer caregivers can also be expected to grow. This anticipated growth will be accompanied by simultaneous increases in the demands placed on caregivers, compounded by the fact that cancer care continues to move further into the outpatient and home settings. The physical and psychosocial health (e.g., comorbidities, depression) of patients and their caregivers are often related, suggesting a need to intervene to improve outcomes for both caregivers and patients.

Specific Research Objectives

Applications submitted to this FOA should propose intervention studies that target a combination of the cancer caregiving outcomes in the following three areas:

1. Healthcare utilization outcomes (e.g., patient readmission to the hospital, number of emergency room visits, caregiver use of health care services, and caregiver use of cancer support services);

2. Caregiver well-being outcomes (lower burden, higher capacity, and better quality of life), and

3. Patient health outcomes (e.g., physical health, symptom burden, health-related quality of life and functioning).

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-318
Funding Opportunity Title: Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.395 — Cancer Treatment Research
93.399 — Cancer Control
Cost Sharing or Matching Requirement: No
Posted Date: Jun 08, 2016
Last Updated Date: Jun 08, 2016
Original Closing Date for Applications: Apr 11, 2019  
Current Closing Date for Applications: Apr 11, 2019  
Archive Date: May 12, 2019
Estimated Total Program Funding:
Award Ceiling: $200,000

Eligibility

Eligible Applicants:
Independent school districts
Private institutions of higher education
Native American tribal governments (Federally recognized)
City or township governments
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Public and State controlled institutions of higher education
County governments
Special district governments
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-318.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Emerging Questions in Cancer Systems Biology (U01)

PAR-16-131
Emerging Questions in Cancer Systems Biology (U01)
Department of Health and Human Services
National Institutes of HealthsymposiumISB

Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects addressing challenging cancer problems using systems biology approaches. In support of this goal, the National Cancer Institute (NCI) has initiated the Cancer Systems Biology Consortium (CSBC) through multiple FOAs. The CSBC network will consist of specialized U01 Research Projects (supported under this FOA), U54 CSBC Research Centers (supported under RFA-CA-15-014), and a U24 Coordinating Center (supported under RFA-CA-15-015).

CSBC Research Projects should address a well-defined, discrete, and circumscribed research question in cancer incorporating quantitative experimentation, analysis, modeling and validation, which are the hallmarks of systems biology. As part of the CSBC, investigators from the Research Projects will have the opportunity to share resources and expertise across the Consortium and participate in Consortium activities and annual meetings.

Background

Research strategies that can integrate across molecular, genetic, and cellular events are required to understand the multivariate nature of cancer and to predict tumor behaviors, efficient treatment opportunities, and, ultimately, patient outcome. Cancer systems biology approaches provide the iterative experimental and analytical toolkit necessary for addressing complex problems in cancer research. Through development of measurement technologies, generation of rich datasets, and employment of computational, mathematical, and algorithmic tools, cancer systems biologists have made important strides in describing cancers as integrated systems of genes, networks, and intercellular interactions. Cancer systems biology is uniquely poised to address various important and/or emerging questions in cancer research that would be difficult, if not impossible, to explore fully using other, less comprehensive approaches.

Along with general cancer-related topics such as the heterogeneous nature of tumors and the widely variable genetic underpinnings of cancer, there are a variety of emerging directions in cancer research that are particularly amenable to a systems approach: (a) decoding dynamic tumor-stroma and/or tumor-immune system interactions; (b) integrating chemical, molecular, structural, network, and localization information across temporal and spatial scales to understand tumor behavior; (c) understanding how individual cell states shape the behavior of tumors and tumor ecosystems; (d) determining how the microbiome affects tumor initiation, progression or treatment; (e) forward engineering of cancer systems through the convergence of synthetic biology and systems biology; (f) bridging the many cancer hierarchies; and (g) utilizing cancer systems biology predictions to inform clinical trial design.

In addition to addressing specific biological hypotheses, the continued success of cancer systems biology depends on the development of new methodologies to address complex and multivariate questions, including new theoretical, mathematical and computational techniques, multi-scale modeling approaches capable of integrating across scales from the molecular to the population level, and new biological tools and systems for informing and testing cancer systems biology generated hypotheses.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-131
Funding Opportunity Title: Emerging Questions in Cancer Systems Biology (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.395 — Cancer Treatment Research
93.396 — Cancer Biology Research
Cost Sharing or Matching Requirement: No
Posted Date: Mar 11, 2016
Last Updated Date: Mar 11, 2016
Original Closing Date for Applications: Nov 23, 2018  
Current Closing Date for Applications: Nov 23, 2018  
Archive Date: Dec 24, 2018
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Small businesses
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Special district governments
Public and State controlled institutions of higher education
County governments
City or township governments
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The National Cancer Institute (NCI) is sponsoring a new Cancer Systems Biology Consortium (CSBC) that includes U54 CSBC Research Centers (RFA-CA-15-014), a U24 CSBC Coordinating Center (RFA-CA-15-015) and, through this FOA, well-defined, discrete and circumscribed Research Projects addressing emerging problems in cancer. The CSBC initiative aims to address challenges in cancer research through the use of experimental biology or population science combined with in silico modeling, multi-dimensional data analysis, and systems engineering.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-131.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Genomic Data Analysis Network: Visualization Genomic Data Center (U24)

RFA-CA-15-019h
Genomic Data Analysis Network: Visualization Genomic Data Center (U24)
Department of Health and Human Services
National Institutes of Health

Research Objectives and Main Requirements for This FOA

Expectations for GDACs in the Genomic Data Analysis Network. As a whole the GDACs must be able to:

  • Implement bioinformatic  pipelines using existing state-of-the-art tools for timely high-throughput processing and integrated analyses of genome-wide data;
  • Develop and implement new bioinformatic and computational tools to capture key biological parameters such as pathway analysis, data integration with visualization, and integrated cancer biology;
  • Develop pipeline and network-wide quality control methods for the system developed as a response to the goals stated above; and
  • Process/integrate analytical data from other components of the network to generate disease level findings and interpretations as well as cross-disease analyses.
  • These goals will necessitate continuous communication and interactions among the members of the network.  Each member of the GDAC group will have distinct functions and capabilities and be responsible for individual analytical components.

Interactions of GDACs with other members of the network. All GDAC awardees, including the Visualization GDAC to be supported under this FOA, must be able to accommodate their activities in the general scheme of the coordinated interactions across the various resources as outlined below.

  • Biospecimen Core Resource (BCR): The BCR serves as the tissue processing center and provides the molecular biomolecules for all CCG-approved projects. Standard operating procedures are used for clinical data collection, sample collection, pathological examination, biomolecule (e.g., DNA and RNA) extractions, quality control, laboratory data collection, and biomolecule distribution to the Cancer Genome Characterization Centers. The samples are required to have patient informed consent for the public release of data or an IRB waiver.
  • Genome Characterization Centers (GCCs): GCCs conduct high-throughput comprehensive genome-wide analyses using validated technologies (e.g., gene expression profiling, detection of chromosomal segment copy numbers alteration) to reveal the spectrum of genomic changes that exist in human tumors and to identify genomic regions for further characterization. The data generated by the characterization centers will be the main (but not only) starting point for the analyses performed by the GDACs.
  • Genomic Data Analysis Network (GDAN): The aggregated capabilities of the awardees from the present FOA and its companions (RFA-CA-15-018 and RFA-CA-15-020) will produce the bulk of the analysis required to interpret the data generated by the GCCs described above. This group will work closely and collaboratively with all other components of the pipeline and be responsive to the necessities of the analysis requests posed by the AWGs that will be formed for each CCG-approved project.
  • Data Management, Storage and Public Access:  The whole of the data generated by CCG-approved projects is presented to the scientific community though publically-available databases that contain not only the raw data and associated metadata, but all of the analysis files generated in the course of each project. At the time of this FOA, that task is performed by the DCC (through project-specific data portals) and CGHub. In the near future, these activities will be consolidated under a single entity, the GDC, where all members of the network will deposit their data.

Required Team Expertise. Each GDAC applicant team must have current expertise in computational data analysis and genomics-specific bioinformatics as well as clinical oncology and/or cancer biology. GDACs would benefit greatly by being jointly led by two investigators: (i) an expert in bioinformatics/computation and (ii) either a clinical oncologist or a cancer biologist who can help to guide the analyses and contribute to the interpretation of the results at the disease-level.

GDACs differ by the proportion of the effort devoted to the development of novel analyses, but each GDAC will be required to develop novel approaches to data analysis and data integration.  The analytical pipelines will be available as a resource to the scientific community for data integration and for advanced translational evaluation of genomic data.  The analytical pipelines may result in valid conclusions which are not 100% concordant due to the different analytical methods used.  The GDACs will need to develop annotation which will be made available along with the pipeline to explain any differences in data interpretation to the research community.

Specific Objectives for Visualization GDAC. The proposed Visualization GDAC must have all the expertise, personnel, instrumentation and throughput capabilities that will be required for the objectives defined below (with additional specific details in Section IV, under “Research Strategy”.)

  • Objective 1: Development of innovative bioinformatics and computational tools and methodologies (requires drawing clinical and biological correlations).
  • Objective 2: Conducting integrative analysis of data sets generated by GCCs using the bioinformatics tools developed by each GDAC.

Objective 3: Implementing an integrative bioinformatics approach utilizing existing bioinformatic tools for timely high-throughput processing and analyses of genome-wide data.

  • Data Sharing Requirements for GDACs:

Public availability of data/information generated by all genomics data resulting from NCI-supported initiatives will be critical to facilitate disease-relevant discoveries of clinical significance and a goal of this initiative. Therefore, sharing as a public resource all rigorously validated data resulting from GDACs is essential for this initiative. For details, see Section IV.2, under “Resource Sharing Plan”.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-CA-15-019
Funding Opportunity Title: Genomic Data Analysis Network: Visualization Genomic Data Center (U24)
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.393 — Cancer Cause and Prevention Research
93.394 — Cancer Detection and Diagnosis Research
93.395 — Cancer Treatment Research
93.396 — Cancer Biology Research
Cost Sharing or Matching Requirement: No
Posted Date: Oct 22, 2015
Creation Date: Oct 22, 2015
Original Closing Date for Applications: Jan 27, 2016  
Current Closing Date for Applications: Jan 27, 2016  
Archive Date: Feb 27, 2016
Estimated Total Program Funding:
Award Ceiling: $660,000
Award Floor:

Eligibility

Eligible Applicants:
County governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
Private institutions of higher education
State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Independent school districts
Special district governments
Native American tribal governments (Federally recognized)
City or township governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples. The acquired knowledge could facilitate and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-019.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)

NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)  Department of Health and Human Services  National Institutes of Health

Purposesupport_cancer_research

The purpose of this funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), is to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research in all areas relevant to the mission of the NCI. By using the R21 mechanism, this FOA will support exploratory/developmental projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, and/or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).

Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. Conversely, long-term projects, or projects designed to increase knowledge in a well-established area, should not be submitted as R21 applications.

Applications submitted under this mechanism should break new ground or extend previous discoveries toward new directions or applications. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant mechanism, which is presently also supported by the NCI Omnibus R03 FOA,PAR-14-007.

Specific Research Objectivescancer research ad2_0

All areas of cancer research relevant to the mission of the NCI are appropriate for projects submitted to this FOA (for a list of extramural research funding programs at the NCI, go tohttp://www.cancer.gov/researchandfunding/extramural). Proposed projects may involve basic, translational, clinical, and/or population research. Examples of relevant areas include but are not limited to studies of: cancer biology; cancer control; cancer diagnosis; cancer disparities; cancer prevention; and cancer treatment.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-15-340
Funding Opportunity Title: NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.393 — Cancer Cause and Prevention Research
93.394 — Cancer Detection and Diagnosis Research
93.395 — Cancer Treatment Research
93.396 — Cancer Biology Research
93.399 — Cancer Control
Cost Sharing or Matching Requirement: No
Posted Date: Sep 1, 2015
Creation Date: Sep 1, 2015
Original Closing Date for Applications: Nov 10, 2015  
Current Closing Date for Applications: Nov 10, 2015  
Archive Date: Dec 11, 2015
Estimated Total Program Funding:
Award Ceiling: $200,000
Award Floor:

ligibility

Eligible Applicants:
City or township governments
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
For profit organizations other than small businesses
Private institutions of higher education
County governments
Native American tribal governments (Federally recognized)
Independent school districts
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-15-340.html

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

Department of Health and Human Services LogoPAR-15-297
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
Department of Health and Human Services
National Institutes of Health

Document Type: Grants Notice
Funding Opportunity Number: PAR-15-297
Funding Opportunity Title: Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.393 — Cancer Cause and Prevention Research
Cost Sharing or Matching Requirement: No

Posted Date:Jul 14, 2015

Creation Date:Jul 14, 2015

Original Closing Date for Applications:Aug 15, 2018 

 Current Closing Date for Applications:Aug 15, 2018  

Archive Date:Sep 15, 2018

Estimated Total Program Funding:

Award Ceiling:

Award Floor:
Eligibility

Eligible Applicants:
County governments
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
City or township governments
For profit organizations other than small businesses
Private institutions of higher education
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Small businesses
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-15-297.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact: